These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 32158625)

  • 41. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.
    Ti W; Wei T; Wang J; Cheng Y
    Front Immunol; 2022; 13():947712. PubMed ID: 35935970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Squamous Carcinoma.
    Zhai WY; Duan FF; Chen S; Wang JY; Zhao ZR; Wang YZ; Rao BY; Lin YB; Long H
    Front Cell Dev Biol; 2022; 10():770550. PubMed ID: 35300428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
    Kim JY; Jung J; Kim KM; Lee J; Im YH
    Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes.
    Deng X; Wang Z; Luo Y; Li Z; Chen L
    Medicine (Baltimore); 2022 Sep; 101(37):e30304. PubMed ID: 36123889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
    Ju Q; Zhao YJ; Ma S; Li XM; Zhang H; Zhang SQ; Yang YM; Yan SX
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1711-1723. PubMed ID: 32356177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Ferroptosis-Related Prognostic Signature Based on Antitumor Immunity and Tumor Protein p53 Mutation Exploration for Guiding Treatment in Patients With Head and Neck Squamous Cell Carcinoma.
    Fan X; Ou Y; Liu H; Zhan L; Zhu X; Cheng M; Li Q; Yin D; Liao L
    Front Genet; 2021; 12():732211. PubMed ID: 34616431
    [No Abstract]   [Full Text] [Related]  

  • 50. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma.
    Hao B; Dong H; Xiong R; Song C; Xu C; Li N; Geng Q
    Comput Biol Med; 2024 Mar; 171():108183. PubMed ID: 38422959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.
    Desrichard A; Kuo F; Chowell D; Lee KW; Riaz N; Wong RJ; Chan TA; Morris LGT
    J Natl Cancer Inst; 2018 Dec; 110(12):1386-1392. PubMed ID: 29659925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
    Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
    BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
    Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
    Front Immunol; 2022; 13():876355. PubMed ID: 35837383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
    Bin Y; Ding P; Liu L; Tong F; Dong X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9051-9070. PubMed ID: 37169931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma.
    Wu G; Wang Y; Wan Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24538. PubMed ID: 35689561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A bioinformatic analysis of the role of TP53 status on the infiltration of CD8+ T cells into the tumor microenvironment.
    El-Arabey AA; Abdel-Hamied HE; Awadalla ME; Alosaimi B; Almanaa TN; Al-Shouli ST; Modafer YA; Alhamdi HW; Abdalla M
    Braz J Med Biol Res; 2023; 56():e12970. PubMed ID: 37878888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma.
    Liao Y; Cheng W; Mou R; Li X; Jia Y
    Sci Rep; 2023 May; 13(1):7553. PubMed ID: 37161020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MMP12 serves as an immune cell-related marker of disease status and prognosis in lung squamous cell carcinoma.
    Zhang W; Li GS; Gan XY; Huang ZG; He RQ; Huang H; Li DM; Tang YL; Tang D; Zou W; Liu J; Dang YW; Chen G; Zhou HF; Kong JL; Lu HP
    PeerJ; 2023; 11():e15598. PubMed ID: 37601247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.